iaso biotherapeutics usa limited
7 articles with iaso biotherapeutics usa limited
-
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
2/14/2022
IASO Biotherapeutics and Innovent Biologics, Inc. jointly announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted Orphan Drug Designation to their fully human anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma.
-
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio
2/14/2022
Innovent Biologics, Inc. together with IASO Biotherapeutics jointly announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has formally granted Orphan Drug Designation to their co-developed fully-human B-cell maturation antigen -targeted chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed/refractory multiple myeloma.
-
Seattle-based Sana Biotechnology went all-in on improving CAR T therapies against B cell cancers in two separate deals announced today.
-
IASO Biotherapeutics and Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting
12/13/2021
IASO Biotherapeutics and Innovent Biologics, Inc. jointly announced the latest data from the phase 1/2 clinical study of a fully human B-cell maturation antigen chimeric antigen receptor T-cell therapy in an oral presentation at the 63rd American Society of Hematology Annual Meeting.
-
Innovent and IASO Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting
12/13/2021
Innovent Biologics, Inc and IASO Biotherapeutics jointly announced the latest data from the phase 1/2 clinical study of a fully human B-cell maturation antigen chimeric antigen receptor T-cell therapy in an oral presentation at the 63rd American Society of Hematology Annual Meeting.
-
IASO Biotheraputics' CT120 Granted Orphan Drug Designation by the U.S. FDA
11/26/2021
IASO Biotherapeutics announced on Oct 26, 2021 that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted the Orphan Drug Designation to the company's in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor -T cell therapy for the treatment of acute lymphoblastic leukemia.
-
IASO Bio Appoints Industry Veteran Dr. Alan Fu Chief Financial Officer
10/19/2021
IASO Biotherapeutics has appointed Dr. Alan Fu as Chief Financial Officer (CFO), reporting to Maxwell Wang, CEO, IASO Bio.